Damora Therapeutics’ Preclinical Data Highlighting Potential Of DMR-001 Accepted For Poster Presentation At 2026 ASH Annual Meeting And Exposition
Benzinga Newsdesk 3 hours ago
News
-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations ---- Trial-in-progress presentation to
-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,
new data to highlight strong activity against additional non-Type 1 mutations --
-- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) --
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the acceptance of preclinical data highlighting the best-in-class potential of DMR-001 for poster presentation at the 2026 ASH Annual Meeting and Exposition. DMR-001 is an investigational pan-mutant, long-acting, Fc-null mutCALR therapy currently being evaluated as a potential treatment for patients with mutCALR-driven ET and MF in the CLARITY-101 Phase 1/1b clinical trial.